pralsetinib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 3 (1)

Interventional (1)

Blueprint Medicines Corporation (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadstage iv nsclc

I am/have/hadchemotherapy regimen

I am/have/hadmetastasis

I am/have/hadlung cancer

I am/have/hadcancer chemotherapy

I am/have/hadbronchogenic carcinoma

I am/have/hadmeasurable disease

I am/have/hadcarcinoma

I am/have/hadcancer therapy

I am/have/hadlung neoplasm

I am/have/hadpulmonary disease

I am/have/hadnon-small cell lung cancer

I am/have/hadmetastatic cancer

I am/have/hadneoplasms by site

I am/have/hadcancer

I am/have/hadstage iv non-small cell lung cancer

I am/have/hadhead and neck neoplasms

I am/have/hadrespiratory tract diseases

I am/have/hadprogressive disease

I am/have/hadlung disease

added new label for I am/have/had

more

I am looking for

I am looking forimmunomodulator

I am looking foradjuvant

I am looking forret inhibitor

I am looking forgemcitabine

I am looking formet inhibitor

I am looking forcisplatin

I am looking forpembrolizumab

I am looking forpemetrexed

I am looking forpralsetinib

I am looking forplatinum-based chemotherapy

I am looking forimmunomodulators

I am looking forcarboplatin

I am looking forimmunostimulants

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 3
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Endocrinology
Recruiting

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC

Patients who have centrally confirmed progressive disease on the control arm have the option to crossover to pralsetinib.

immunomodulator

stage iv nsclc

chemotherapy regimen

ret inhibitor

lung cancer

0 views
19 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2026 All rights reserved.